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Background: Risks of repeat thoracotomy can be reduced if thoracic computed tomographic angiography (CTA) is used to guide preventive 
surgical strategies (PSS) such as peripheral cardiopulmonary bypass, circulatory arrest and non-median sternotomy. We sought to define the cost-
effectiveness of CTA using a Markov model.
Methods: We studied outcomes & costs of CTA & non-CTA strategies in a modeled cohort of 10,000 patients undergoing redo coronary artery 
bypass grafting (CABG). PSS were anticipated to follow identification of risk by CTA. Transitions, costs & utilities were informed by our experience & 
the literature. Sensitivity analyses included testing a range of costs of CTA & PSS on model outcome.
Results: In the reference case, cost & QALYs accrued with the use of CTA ($74,869, 4.63 QALYs) were slightly higher than non-use ($73,471, 4.59 
QALYs), yielding an incremental cost-effectiveness ratio (ICER) of $34,950/QALY. Cost of PSS (equipment & operating time) is the most significant 
determinant of ICER, with a threshold of $12,000. In the reference case (cost of CTA ~$300), identification & avoidance of potential procedural 
difficulties with CTA rendered it cost-effective if the cost of PSS was <$12,000. Cost of CTA did not adversely influence outcomes across a broad 
range of imputed values (see Figure).
Conclusion: The cost of CTA is justified in the setting of redo CABG, as it aids in appropriate selection of PSS. Cost-effectiveness is more influenced 
by the costs of subsequent PSS than by the cost of CTA.
 
